These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26052399)

  • 1. Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin.
    Ampuero J; Romero-Gomez M
    World J Hepatol; 2015 May; 7(8):1105-11. PubMed ID: 26052399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
    Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
    Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cross-talk between PI3K/Akt and MEK/ERK pathways regulates human hepatocellular carcinoma cell cycle progression under endoplasmic reticulum stress].
    Yan DM; Dai RY; Duan CY; Chen SK; Liu YP; Chen CN; Li H
    Zhonghua Gan Zang Bing Za Zhi; 2010 Dec; 18(12):909-14. PubMed ID: 21205476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
    Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
    Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tanshinone IIA can inhibit MiaPaCa‑2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways.
    Su CC
    Oncol Rep; 2018 Nov; 40(5):3102-3111. PubMed ID: 30226540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis.
    Wu J; Wong WW; Khosravi F; Minden MD; Penn LZ
    Cancer Res; 2004 Sep; 64(18):6461-8. PubMed ID: 15374955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma.
    Dimri M; Satyanarayana A
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32093152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies.
    Gnoni A; Licchetta A; Memeo R; Argentiero A; Solimando AG; Longo V; Delcuratolo S; Brunetti O
    Medicina (Kaunas); 2019 Nov; 55(12):. PubMed ID: 31766556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma.
    Yang S; Liu G
    Oncol Lett; 2017 Mar; 13(3):1041-1047. PubMed ID: 28454211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway.
    Wang T; Seah S; Loh X; Chan CW; Hartman M; Goh BC; Lee SC
    Oncotarget; 2016 Jan; 7(3):2532-44. PubMed ID: 26565813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
    Li C; Liu VW; Chan DW; Yao KM; Ngan HY
    Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
    J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphatidylinositol 3-Kinase/Akt and MEK/ERK Signaling Pathways Facilitate Sapovirus Trafficking and Late Endosomal Acidification for Viral Uncoating in LLC-PK Cells.
    Soliman M; Kim DS; Park JG; Kim JY; Alfajaro MM; Baek YB; Cho EH; Park CH; Kang MI; Park SI; Cho KO
    J Virol; 2018 Dec; 92(24):. PubMed ID: 30282712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways.
    Bibollet-Bahena O; Almazan G
    J Neurochem; 2009 Jun; 109(5):1440-51. PubMed ID: 19453943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting AMPK, mTOR and β-Catenin by Combined Metformin and Aspirin Therapy in HCC: An Appraisal in Egyptian HCC Patients.
    Abdelmonsif DA; Sultan AS; El-Hadidy WF; Abdallah DM
    Mol Diagn Ther; 2018 Feb; 22(1):115-127. PubMed ID: 29094287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational analysis of the RAS/RAF/MEK/ERK signaling pathway in 260 Han Chinese patients with cervical carcinoma.
    Zou Y; Liu FY; Wu J; Wan L; Fang SF; Zhang ZY; Luo Y; Chen MH; Huang MZ; He M; Huang OP
    Oncol Lett; 2017 Aug; 14(2):2427-2431. PubMed ID: 28781678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Potential of Isoprenoids in Adjuvant Cancer Therapy to Reduce Adverse Effects of Statins.
    Mo H; Jeter R; Bachmann A; Yount ST; Shen CL; Yeganehjoo H
    Front Pharmacol; 2018; 9():1515. PubMed ID: 30662405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.